New analysis links reduced brain atrophy with blarcamesine to better cognition and daily functioning in early Alzheimer’s.

Researchers are calling for more studies to determine whether lymphovenous anastomosis (LVA), a surgical procedure that helps clear molecular waste from the brain, might benefit people with ...

The European Commission has approved Eli Lilly‘s monthly infusion therapy Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease. The treatment targets sticky protein clumps, or ...

The U.S. Food and Drug Administration (FDA) has approved a more gradual titration dosing schedule for Kisunla (donanemab) for people with early symptomatic Alzheimer’s disease based on evidence that ...

A new patient advocacy organization, the ApoE4 Alzheimer’s Alliance, has launched in the U.S., with a goal of helping advance both supportive policies and the development of treatments for people with ...

Age at menopause may interact with factors related to the health of synapses, or nerve cell connections, to influence the risk of Alzheimer’s disease in women, a study found. Associations between ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease. The company ...

Being started on a smaller dose of the approved early Alzheimer’s disease therapy Kisunla (donanemab) — by shifting one vial from the first to the third infusion treatment — reduces the risk of ARIA-E ...

Alzamend Neuro has determined the maximum tolerated dosage of AL001, its experimental lithium therapy for Alzheimer’s disease and other disorders, that will be used in future clinical trials. The ...

Higher exposure to outdoor light at night may increase the risk of developing Alzheimer’s disease, especially in people younger than 65, according to a study that drew on Medicare records and ...

After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing ...